An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Prior treatment

• Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
• History of seizure including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization).

Other illness

• Known or suspected brain metastasis or active leptomeningeal disease
• History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer

• Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
• Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy
• Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bone disease
• No prior treatment with cytotoxic chemotherapy
• Asymptomatic or mildly symptomatic from prostate cancer